Contraceptive and cholesterol-lowering drug combination (BaP) used to treat cancer 15 May 2015 | By Victoria White The BaP combination of a cholesterol-lowering drug, bezafibrate and a contraceptive steroid could be an effective treatment for a range of cancers.
Lilly and Sanford-Burnham to collaborate to discover immunological therapies 15 May 2015 | By Victoria White Eli Lilly and Company and Sanford-Burnham Medical Research Institute are to collaborate to discover and develop immunological therapies...
Anisina confirmed as effective anti-cancer agent in preclinical studies 14 May 2015 | By Victoria White Novogen has confirmed that drug candidate, Anisina, is an effective monotherapy against human melanoma in an animal model...
Acucela announces publication of preclinical data for emixustat 14 May 2015 | By Victoria White Acucela has announced the publication of preclinical data related to the Company’s investigational drug candidate emixustat hydrochloride...
Antibiotic Research UK welcomes the O’Neill Commission’s recommendation to create $2b global fund to tackle antibiotic resistance 14 May 2015 | By Victoria White Antibiotic Research UK has welcomed this latest report to come from Jim O’Neill's Review on Antimicrobial Resistance and has endorses its recommendations...
Immunomic Therapeutics awarded $1.2m to develop peanut allergy treatment 13 May 2015 | By Victoria White Immunomic Therapeutics has been awarded a US $1.2 million grant for the development of its ARA-LAMP-vax technology against peanut allergies...
Sanofi exercises option on second therapeutic programme with Selecta Biosciences to develop a treatment for coeliac disease 13 May 2015 | By Victoria White Under the terms of an existing agreement with Selecta, Sanofi has exercised its option to an exclusive license to develop a treatment of coeliac disease...
Genethon and Selecta Biosciences to research repeat dosing for gene therapies 13 May 2015 | By Victoria White Genethon and Selecta Biosciences have announced an ongoing research collaboration with the goal of enabling repeat dosing for gene therapies...
Soligenix enters agreement with Emergent BioSolutions to develop ricin vaccine RiVax 13 May 2015 | By Victoria White Soligenix has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for RiVax...
Invectys initiates Phase I clinical trial evaluating INVAC-1 therapeutic vaccine for cancer patients 13 May 2015 | By Victoria White A Phase I clinical trial of INVAC-1, an innovative therapeutic DNA vaccine, which specifically targets the telomerase enzyme (hTERT), has commenced...
New “map” of TTLL7 protein helps researchers understand cellular transport 12 May 2015 | By Scientists from TSRI and NIH have mapped out the structure of an important protein involved in cellular function and nervous system development - TTLL7...
Significant progress made towards individualised cancer immunotherapy 12 May 2015 | By Victoria White Mainz-based researchers have made significant advances with regard to the development of individualised cancer immunotherapy strategies...
Haplogen and Cyclenium Pharma announce research and development collaboration 12 May 2015 | By Victoria White Cyclenium Pharma and Haplogen have signed a research agreement aimed at the discovery of novel pharmaceutical candidates in multiple disease areas...
BioNTech and Lilly enter into cancer immunotherapy research collaboration 12 May 2015 | By Victoria White BioNTech and Lilly are to collaborate to identify and validate novel tumour targets and their corresponding TCRs in one or more types of cancer...
FDA grants QIDP and Fast Track Designations to CD101 IV for the treatment of candidemia 11 May 2015 | By Victoria White Cidara Therapeutics has announced that the FDA has designated the Company’s lead antifungal product candidate, CD101 IV, as a QIDP with Fast Track status...
